6:33 PM
 | 
Dec 17, 2012
 |  BC Extra  |  Financial News

Galena Biopharma planning follow-on

Galena Biopharma Inc. (NASDAQ:GALE) said it is planning a follow-on underwritten by Piper Jaffray. Galena's NeuVax is in the Phase III PRESENT trial to...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >